Animal-Friendly Affinity Reagents: Replacing the Needless in the Haystack.

Area of Science:

• Biotechnology
• Immunology
• Regulatory Science

Background:

• The global antibody industry relies heavily on animal immunization, utilizing millions of animals annually.
• Despite the availability of advanced animal-friendly affinity reagents (AFAs) like those from naïve B lymphocyte and synthetic recombinant phage display technologies, animal use persists.
• This reliance overlooks significant opportunities for animal use reduction.

Purpose of the Study:

• To address the continued use of animals in antibody production despite viable alternatives.
• To advocate for the implementation of Directive 2010/63/EU, which mandates the use of alternatives when available.
• To propose an EU-led strategy for replacing animal-based antibody production.

Main Methods:

• Analysis of current antibody production practices and the availability of animal-friendly affinity reagents (AFAs).
• Engagement in discussions with the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) and the Directorate General for Environment.
• Development of a proposed EU-led replacement strategy for antibody production.

Main Results:

• Identified a significant gap between the availability of animal-friendly alternatives and their adoption in the antibody industry.
• Initiated dialogue with key EU regulatory bodies to foster a strategy for implementing Directive 2010/63/EU.
• Outlined necessary measures including avoiding outsourcing, regulating commercial production, and supporting antibody producers.

Conclusions:

• The antibody industry must transition towards animal-friendly affinity reagents (AFAs) to comply with ethical and regulatory standards.
• An EU-led strategy is crucial for facilitating the widespread adoption of alternatives and reducing animal use.
• Regulatory measures and industry support are essential for a successful shift away from animal immunization.